Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
JAZZ moved a median of +0.01% 30 minutes after news, and +0.09% by the close. How JAZZ actually reacts to news — the realized, point-in-time move the market made, measured across 543 labeled events over the last three years with zero look-ahead.
JAZZ’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 540 |
| 30-min | +0.01% | 50% | 542 |
| 60-min | -0.09% | 47% | 542 |
| to close | +0.09% | 53% | 517 |
| Middle 50% of JAZZ reactions | -0.55% to +0.49% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 543 |
Half of all Jazz Pharmaceuticals plc - Ordinary Shares news events land between -0.55% and +0.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How JAZZ reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 25 | 0.00% | 40% | -0.39% |
| Analyst downgrades | 19 | +0.22% | 68% | -0.49% |
| Coverage initiations | 22 | -0.17% | 27% | -0.48% |
| Rating reiterations | 176 | +0.09% | 53% | +0.08% |
| Price-target raises | 37 | +0.01% | 51% | +0.63% |
| Price-target cuts | 26 | -0.12% | 46% | -0.24% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how JAZZ ranks against every other measured name →
That’s how JAZZ usually reacts — get an email when it moves on news →Email me when JAZZ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JAZZ's baseline. Nothing else.
Recent JAZZ events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Jazz Pharmaceuticals For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | -1.81% | |
| Form 8-K Jazz Pharmaceuticals For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +0.20% | |
| Form 8-K Jazz Pharmaceuticals For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | -2.42% | |
| Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences | Press release | PR Newswire | -0.84% | -2.42% | |
| Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -0.55% | +0.26% | |
| Form 8-K Jazz Pharmaceuticals For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | -2.57% | |
| Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA | Press release | PR Newswire | +1.72% | +3.85% | |
| Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases | Press release | PR Newswire | +0.58% | +0.59% | |
| Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases | Press release | PR Newswire | -0.18% | -3.15% | |
| Form 8-K Jazz Pharmaceuticals For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | -3.15% | |
| U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma | Press release | PR Newswire | +0.98% | +1.83% | |
| Form 8-K Jazz Pharmaceuticals For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | — | |
| Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | Press release | PR Newswire | +0.66% | — | |
| Form 10-Q Jazz Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.78% | +2.44% | |
| Form 8-K Jazz Pharmaceuticals For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | +2.44% | |
| Form 8-K Jazz Pharmaceuticals For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | -0.55% | |
| Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results | Press release | PR Newswire | -1.78% | +2.44% | |
| Form 8-K Jazz Pharmaceuticals For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | -0.55% | |
| Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 | Press release | PR Newswire | -0.21% | +3.91% | |
| Form DEFA14A Jazz Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -0.17% | +1.40% | |
| Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | Press release | PR Newswire | -0.53% | +0.19% | |
| Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia | Press release | PR Newswire | -0.53% | +0.19% | |
| Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer | Press release | PR Newswire | +0.40% | -2.07% | |
| Form ARS Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.42% | -3.25% | |
| Form DEF 14A Jazz Pharmaceuticals For: Jul 23 | SEC filing · Form DEF | SEC EDGAR | -0.42% | -3.25% | |
| Form DEFA14A Jazz Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -0.42% | -3.25% | |
| Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia | Press release | PR Newswire | +0.77% | +2.53% | |
| Form 8-K Jazz Pharmaceuticals For: May 25 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -1.05% | |
| Form PRE 14A Jazz Pharmaceuticals For: Jul 23 | SEC filing · Form PRE | SEC EDGAR | +0.16% | -1.05% | |
| Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Press release | PR Newswire | +1.06% | -0.67% | |
| Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.66% | +1.55% | |
| Form 10-Q Jazz Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.46% | -0.04% | |
| Form 8-K Jazz Pharmaceuticals For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -0.04% | |
| Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results | Press release | PR Newswire | -0.46% | -0.04% | |
| Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Press release | PR Newswire | +0.08% | +1.54% | |
| Form 10-K/A Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.08% | +1.54% | |
| Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) | Press release | PR Newswire | +0.20% | +0.83% | |
| Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 | Press release | PR Newswire | +0.20% | +0.83% | |
| Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting | Press release | PR Newswire | +0.10% | +1.89% | |
| Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference | Press release | PR Newswire | +0.11% | +0.45% | |
| American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education | Press release | PR Newswire | -0.05% | +1.40% | |
| Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 | Press release | PR Newswire | -1.07% | -1.24% | |
| Form 10-K Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.07% | +9.35% | |
| Form 8-K Jazz Pharmaceuticals For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +9.35% | |
| Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance | Press release | PR Newswire | +0.07% | +9.35% | |
| Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.13% | +0.45% | |
| Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 | Press release | PR Newswire | -0.05% | +0.70% | |
| Form 8-K Jazz Pharmaceuticals For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | +0.65% | |
| Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer | Press release | PR Newswire | +2.23% | -0.11% | |
| Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit | Press release | PR Newswire | +0.78% | +0.60% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JAZZ section they belong to.
Where else JAZZ is measured.
JAZZ earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ANTHERA PHARMS INC NEW (ANTH) | 546 | -0.01% | 40% |
| GENEREX BIOTECHNOLOGY (GNBT) | 546 | 0.00% | 49% |
| FLEX PHARMA (FLKS) | 541 | -0.16% | 43% |
| OSIRIS THERAPEUTICS (OSIR) | 538 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Jazz Pharmaceuticals plc - Ordinary Shares's median reaction calculated?
Every labeled JAZZ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 543 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of JAZZ's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JAZZ's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.